Berenberg analyst Scott Bardo says he “would not dismiss the prospects for renewed talks” between Qiagen (NYSE:QGEN) and its suitors “at some point in the future.”
The analyst says talks with Qiagen revealed price wasn’t the primary impediment to a deal. The company cited timing, capital access, and legal hurdles as the core issues.
On Tuesday, QGEN shares plunged after the company decided to remain a standalone business after a strategic review.
QGEN shares are currently down 21.5% to $32.55.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.